Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer

Dr. Arteaga serves on an Advisory Board for Novartis and was a consultant for AstraZeneca from 2015 to 2016. All other authors declare that they have no competing interests.

http://link.springer.com/10.1007/s40261-019-00748-x

Source: Clinical Drug Investigation - January 12, 2019 Category: Drugs & Pharmacology Source Type: research